Retinopathy of Prematurity-Incidence Today

Zin, Andréa; Gole, Glen A.

doi:10.1016/j.clp.2013.02.001

Cited by 158 publications

(130 citation statements)

References 55 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Low birth weight, low gestational age and prolonged exposure to supplementary oxygen therapy following delivery are associated with ROP 3 . ROP develops in 16% of all premature births, 60% of infants with birth weight of less than 1500g and 65% if the birth weight is less than 1250g.…”

Section: Discussionmentioning

confidence: 99%

“…ROP occurs in extremely low birth weight infants in high income countries, with declining incidence in last few decades. Due to high rates of premature birth and increasing resuscitation of premature infants with suboptimal standards of care, a third epidemic of ROP has ensued in middle income countries 3 Differential diagnoses include persistent hyperplastic primary vitreous (PHPV) which is typically unilateral and occurs in term babies and familial exudative vitreo retinopathy a genetic disorder that disrupts retinal vascularization in full term infants 8 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of ultrasound in retinopathy of prematurity: a case report

Khaladkar

Kotkar

Kulkarni

et al. 2018

Sri Lanka J. Radiol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Role of ultrasound in retinopathy of prematurity: a case report

Khaladkar

Kotkar

Kulkarni

et al. 2018

Sri Lanka J. Radiol.

View full text Add to dashboard Cite

“…Countries with infant mortality rates (IMRs) >60/1 000 live births do not usually have NICUs; therefore, premature babies do not survive and these countries have a low incidence of ROP. [2] Countries with IMRs of 9 -60/1 000 live births represent the highest burden of blindness caused by ROP, as more premature babies survive in NICUs where oxygen administration may be poorly monitored. [1] SA's IMR for 2011 was 35/1 000 live births.…”

Section: Researchmentioning

confidence: 99%

“…The second epidemic started in the 1970s as a result of the higher survival rates of extremely premature babies secondary to advances in neonatal intensive care units (NICUs). [1] A third epidemic of ROP is currently said to be occurring in middleincome countries [2] such as South Africa (SA). Reasons for this include improved survival of premature babies in these countries, together with a lack of adequate monitoring of oxygen therapy.…”

Section: Researchmentioning

confidence: 99%

An evaluation of the screening for retinopathy of prematurity in very-low-birth-weight babies at a tertiary hospital in Johannesburg, South Africa

Dadoo

Ballot

2016

S Afr J CH

View full text Add to dashboard Cite

Background. Retinopathy of prematurity (ROP) is a leading cause of blindness for very-low-birth-weight (VLBW, <1 500 g) babies. ROP screening identifies babies that require treatment to prevent major visual impairment. Objectives. To evaluate the screening for ROP at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) by reviewing the number of babies screened according to the CMJAH guidelines, the grades of ROP found and the treatment modality received. Methods. This was a retrospective record review of VLBW babies born between 1 January 2013 and 31 December 2013 at CMJAH, whether inborn or transferred in. The babies were divided into two groups based on age at final outcome. Final outcome was defined as death, discharge or transfer out of the unit. The 'early' outcome group had their final outcome before day 28 of life. The 'late' outcome group had their final outcome at day 28 or more of life. The early outcome group qualified for outpatient ROP screening and the late outcome group qualified for inpatient ROP screening.Results. There were a total of 572 VLBW babies at CMJAH during this time period. The babies had a mean birth weight of 1 127 (standard deviation (SD) 244.75) g and gestational age of 29 (2.743) weeks. The mean duration of stay was 29 (21.66) days and there were 309 female babies. Of these 572 babies, 304 comprised the early outcome group and 268 comprised the late outcome group. In the early outcome group babies who were transferred out of the unit or died were excluded; therefore the remaining 147 babies discharged home qualified for outpatient ROP screening. Inpatient ROP screening was carried out in 36/147 (24.4%) of these babies (not in accordance with ROP screening guidelines). ROP was documented in 4/36 (11.1%). Outpatient ROP screening records were unavailable. Exclusions from the late outcome group included five babies. In the late outcome group 111/263 (42.2%) were screened for ROP. ROP was found in 17%. One baby required treatment with intravitreal antivascular endothelial growth factor (VEGF) and three babies required surgery. Conclusions. More than half of the babies in the late outcome group were not screened during their stay (57.8%). More than one-third of babies were discharged prior to reaching the current recommended age for screening. Efforts need to be intensified to identify and screen all eligible babies prior to discharge. Outpatient ROP screening is not well documented; therefore prevalence cannot be established.

show abstract

“…In this part of world, ROP is considered the most common cause of blindness in childhood. ROP is likely to become a growing problem in India, China and other Asian countries as these countries expand their providing care for premature babies (Di Fiore et al, 2010;Zin and Gole, 2013;Liu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity

et al. 2014

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is known as an abnormal development of the blood capillaries from the eyes retina, and it is met to those infants that were born too early (premature) as its name suggests. Bevacizumab or Avastin belongs to the class of monoclonal antibodies and it is a possible treatment for those patients who have been diagnosed with a recurrent malignant glioma or other cancers due to its behavior to bind selectively to vascular endothelial growth factor (VEGF). In this study, eye drops based on a polyurethane carrier used for bevacizumab were obtained and the degradation of this carrier was studied for three weeks in two different media: simulated body fluid (SBF) and phosphate buffered saline (PBS); the influence of ultrasounds on the degradation of polyurethane carrier was also evaluated. The obtained results suggest that the polyurethane carrier presents a very slow degradation which is beneficial for drugs which require low release rates and on the other hand, the concentrations of the degradation products remain at a low level.DOI: http://dx.doi.org/10.3329/icpj.v3i6.18759 International Current Pharmaceutical Journal, May 2014, 3(6): 275-279

show abstract

Retinopathy of Prematurity-Incidence Today

Cited by 158 publications

References 55 publications

Role of ultrasound in retinopathy of prematurity: a case report

Role of ultrasound in retinopathy of prematurity: a case report

An evaluation of the screening for retinopathy of prematurity in very-low-birth-weight babies at a tertiary hospital in Johannesburg, South Africa

Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity

Contact Info

Product

Resources

About